Overview

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Status:
Recruiting

Trial end date:
2023-08-21

Target enrollment:

Participant gender:

Summary

The main objective of this study is to evaluate the efficacy of ALIS (amikacin liposome inhalation suspension) + Azithromycin + Ethambutol compared to the ELC (empty liposome control) + Azithromycin + Ethambutol on participant reported respiratory symptoms at Month 13.

Phase:

Phase 3

Details

Lead Sponsor:

Insmed Incorporated

Treatments:

Amikacin
Azithromycin
Ethambutol